Dr. Yuan C. Yuan

Oncology | Hematology Oncology

Cedars Sinai

10 Congress St, Suite 210,

Pasadena, CA

Clinical Trials:Currently Recruiting for 3 Trials

Offers Telehealth

Cedars Sinai

10 Congress St, Suite 210,

Pasadena, CA

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Yuan Yuan is an Oncologist and a Hematologist Oncology provider in Pasadena, California. Dr. Yuan is rated as an Experienced provider by MediFind in the treatment of Parapneumonic Pleural Effusion. Her top areas of expertise are Triple-Negative Breast Cancer, Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Sleeve Gastrectomy.

Her clinical research consists of co-authoring 314 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Hematology Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Cedars-Sinai Medical Center

Huntington Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Locations

CEDARS-SINAI MEDICAL CARE FOUNDATION
10 Congress St, Suite 210, Pasadena, CA 91105

Call: 310-423-1153

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

Enrollment Status: Recruiting

Publish Date: August 06, 2025

Intervention Type: Drug

Study Drugs: Standard Therapy, AMG 386 +/- Trastuzumab, AMG 479 (Ganitumab)+Metformin, MK-2206 +/- Trastuzumab, AMG 386+Trastuzumab, T-DM1+Pertuzumab, Pertuzumab+Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 Cycle, Talazoparib+Irinotecan, Patritumab+Trastuzumab, Pembrolizumab - 8 Cycle, SGN-LIV1A, Durvalumab+Olaparib, SD-101+Pembrolizumab, Tucatinib+Trastuzumab and Pertuzumab, Cemiplimab, Cemiplimab+REGN3767, Trilaciclib +/- Trastuzumab+Pertuzumab, SYD985 ([vic-]Trastuzumab Duocarmazine), Oral Paclitaxel+Encequidar+Dostarlimab (TSR-042)+Carboplatin +/- Trastuzumab, Oral Paclitaxel+Encequidar+Dostarlimab (TSR-042) +/- Trastuzumab

Study Phase: Phase 2

A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination With Immune Checkpoint Inhibitor in Patients With Metastatic Triple Negative Breast Cancer

Enrollment Status: Recruiting

Publish Date: July 23, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Adoptive Immunotherapy for Advanced MUC1* Positive Breast Cancer With Autologous T Cells Engineered to Express a Chimeric Antigen Receptor, huMNC2-CAR44 or huMNC2-CAR22, Specific for a Cleaved Form of MUC1 (MUC1*)

Enrollment Status: Recruiting

Publish Date: June 18, 2023

Intervention Type: Biological

Study Drugs: huMNC2-CAR44 CAR T cells, huMNC2-CAR44 CAR T cells @ RP2D

Study Phase: Phase 1

A Phase I, First-in-Human Study of Intratumoral Administration of CF33-hNIS-antiPDL1, A Novel Chimeric Oncolytic Poxvirus Encoding Human Sodium Iodide Symporter (HNIS) in Patients With Metastatic Triple Negative Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: October 06, 2025

Intervention Type: Biological

Study Drug: CF33-hNIS-antiPDL1

Study Phase: Phase 1

A Phase II Study of U3-1402 (Patritumab Deruxtecan) in Patients With Metastatic Breast Cancer

Enrollment Status: Completed

Publish Date: June 22, 2025

Intervention Type: Drug

Study Drug: U3-1402

Study Phase: Phase 2

Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: March 03, 2025

Intervention Type: Drug, Other

Study Drugs: carboplatin, nab-paclitaxel

Study Phase: Phase 2

Phase II Study of the Combination of Pembrolizumab, Letrozole, and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: January 29, 2025

Intervention Type: Drug, Other, Biological

Study Drugs: Letrozole, Palbociclib, Pembrolizumab

Study Phase: Phase 2

A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)

Enrollment Status: Completed

Publish Date: February 20, 2024

Intervention Type: Drug, Other, Biological

Study Drugs: Enobosarm, Pembrolizumab

Study Phase: Phase 2

A Phase I/IB Study of Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Patients With Metastatic Triple Negative Breast Cancer

Enrollment Status: Completed

Publish Date: February 20, 2024

Intervention Type: Other, Drug

Study Drugs: Atezolizumab, Capecitabine, Carboplatin, Ipatasertib, Paclitaxel

Study Phase: Phase 1/Phase 2

A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification

Enrollment Status: Completed

Publish Date: October 17, 2023

Intervention Type: Drug

Study Phase: Phase 2

Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer

Enrollment Status: Completed

Publish Date: July 05, 2023

Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast Cancer

Enrollment Status: Completed

Publish Date: June 18, 2023

Intervention Type: Other, Drug

Study Drug: Neratinib

Study Phase: Phase 2

A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors

Enrollment Status: Suspended

Publish Date: April 20, 2023

Intervention Type: Biological

Study Drug: Chimeric antigen receptor T cell therapy

Study Phase: Phase 1

Phase I/IB Trial of Eribulin and Everolimus in Patients With Triple Negative Metastatic Breast Cancer

Enrollment Status: Completed

Publish Date: July 05, 2022

Intervention Type: Other, Drug

Study Phase: Phase 1

Comparative Effects of Ribociclib and Palbociclib on Circulating and Tumor Infiltrating Myeloid Cells in Metastatic Breast Cancer Patients

Enrollment Status: Withdrawn

Publish Date: June 09, 2022

Intervention Type: Procedure, Other

Study Phase: Not Applicable

View 12 Less Clinical Trials

314 Total Publications

Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology.

Journal: bioRxiv : the preprint server for biology

Published: August 01, 2025

View All 314 Publications

Similar Doctors

Advanced in Parapneumonic Pleural Effusion

Dr. Weber Chen

Hematology Oncology

Advanced in Parapneumonic Pleural Effusion

Dr. Weber Chen

Hematology Oncology

50 Alessandro Place, Suite 310,

Pasadena, CA

(0.2 miles away)

626-288-0008

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Weber Chen is a Hematologist Oncology provider in Pasadena, California. Dr. Chen is rated as a Distinguished provider by MediFind in the treatment of Parapneumonic Pleural Effusion. His top areas of expertise are Thrombocytopenia, Angiosarcoma, Inflammatory Breast Cancer, and Febrile Neutropenia. Dr. Chen is currently accepting new patients.

Advanced in Parapneumonic Pleural Effusion

Dr. Daniel J. Kim

Hematology Oncology | Oncology | Hematology

Advanced in Parapneumonic Pleural Effusion

Dr. Daniel J. Kim

Hematology Oncology | Oncology | Hematology

City Of Hope Medical Foundation

209 Fair Oaks Ave,

South Pasadena, CA

(0.7 miles away)

626-396-2900

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Daniel Kim is a Hematologist Oncology specialist and an Oncologist in South Pasadena, California. Dr. Kim is rated as a Distinguished provider by MediFind in the treatment of Parapneumonic Pleural Effusion. His top areas of expertise are Stomach Cancer, Chronic Familial Neutropenia, Agranulocytosis, and Blood Clots.

Experienced in Parapneumonic Pleural Effusion

Dr. Ronald Tang

Hematology Oncology

Experienced in Parapneumonic Pleural Effusion

Dr. Ronald Tang

Hematology Oncology

50 Alessandro Place, Suite 310,

Pasadena, CA

(0.2 miles away)

626-288-0008

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Ronald Tang is a Hematologist Oncology provider in Pasadena, California. Dr. Tang is rated as a Distinguished provider by MediFind in the treatment of Parapneumonic Pleural Effusion. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Neuroendocrine Carcinoma of the Cervix, and Cervical Cancer. Dr. Tang is currently accepting new patients.

VIEW MORE PARAPNEUMONIC PLEURAL EFFUSION DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Yuan's expertise for a condition

ConditionClose